Guideline based eligibility for primary prevention statin therapy - Insights from the North India ST-elevation myocardial infarction registry (NORIN-STEMI).

[1]  Deepak L. Bhatt,et al.  Design and rationale of the North Indian ST‐Segment Elevation Myocardial Infarction Registry: A prospective cohort study , 2019, Clinical cardiology.

[2]  P. Libby,et al.  Low-Density Lipoprotein Cholesterol After an Acute Coronary Syndrome: How Low to Go? , 2019, Current Cardiology Reports.

[3]  Chiadi E. Ndumele,et al.  2018 AHA/ACC/AACVPR/AAPA/ABC/ACPM/ADA/AGS/APhA/ASPC/NLA/PCNA Guideline on the Management of Blood Cholesterol: Executive Summary: A Report of the American College of Cardiology/American Heart Association Task Force on Clinical Practice Guidelines. , 2019, Journal of the American College of Cardiology.

[4]  M. Budoff,et al.  Association of Estimated Long-term Exposure to Air Pollution and Traffic Proximity With a Marker for Coronary Atherosclerosis in a Nationwide Study in China , 2019, JAMA network open.

[5]  A. Jha,et al.  Getting Coverage Right for 500 Million Indians. , 2019, The New England journal of medicine.

[6]  D. Prabhakaran,et al.  Tackling the Burden of Cardiovascular Diseases in India. , 2019, Circulation. Cardiovascular quality and outcomes.

[7]  Deepak L. Bhatt,et al.  Twenty Year Trends and Sex Differences in Young Adults Hospitalized With Acute Myocardial Infarction: The ARIC Community Surveillance Study , 2019, Circulation.

[8]  J Wouter Jukema,et al.  Alirocumab and Cardiovascular Outcomes after Acute Coronary Syndrome , 2018, The New England journal of medicine.

[9]  D. Prabhakaran,et al.  Implications of the New American College of Cardiology Guidelines for Hypertension Prevalence in India , 2018, JAMA internal medicine.

[10]  V. Paul,et al.  Informing NCD control efforts in India on the eve of Ayushman Bharat , 2018, The Lancet.

[11]  K. Watson,et al.  Atherosclerotic Cardiovascular Disease in South Asians in the United States: Epidemiology, Risk Factors, and Treatments: A Scientific Statement From the American Heart Association. , 2018, Circulation.

[12]  Mark D. Huffman,et al.  Cardiovascular Diseases in India Compared With the United States. , 2018, Journal of the American College of Cardiology.

[13]  L. Aminde,et al.  Primary and secondary prevention interventions for cardiovascular disease in low-income and middle-income countries: a systematic review of economic evaluations , 2018, Cost Effectiveness and Resource Allocation.

[14]  Deepak L. Bhatt,et al.  Electronic health records and outpatient cardiovascular disease care delivery: Insights from the American College of Cardiology’s PINNACLE India Quality Improvement Program (PIQIP) , 2018, Indian heart journal.

[15]  Deepak L. Bhatt,et al.  Cardiovascular Risk and Statin Eligibility of Young Adults After an MI: Partners YOUNG-MI Registry. , 2017, Journal of the American College of Cardiology.

[16]  A. Keech,et al.  Evolocumab and Clinical Outcomes in Patients with Cardiovascular Disease , 2017, The New England journal of medicine.

[17]  N. Cook,et al.  The Pooled Cohort Equations 3 Years On: Building a Stronger Foundation. , 2016, Circulation.

[18]  M. Phipps,et al.  Statin Use for the Primary Prevention of Cardiovascular Disease in Adults: US Preventive Services Task Force Recommendation Statement. , 2016, JAMA.

[19]  E. Boerwinkle,et al.  Genetic Risk, Adherence to a Healthy Lifestyle, and Coronary Disease. , 2016, The New England journal of medicine.

[20]  A. Hoes,et al.  2016 European Guidelines on cardiovascular disease prevention in clinical practice. , 2016, Revista espanola de cardiologia.

[21]  V. Fuster,et al.  A Simple Disease-Guided Approach to Personalize ACC/AHA-Recommended Statin Allocation in Elderly People: The BioImage Study. , 2016, Journal of the American College of Cardiology.

[22]  D. Prabhakaran,et al.  Cardiovascular Diseases in India: Current Epidemiology and Future Directions , 2016, Circulation.

[23]  Olle Melander,et al.  Genetic risk, coronary heart disease events, and the clinical benefit of statin therapy: an analysis of primary and secondary prevention trials , 2015, The Lancet.

[24]  Mary Cushman,et al.  Validation of the atherosclerotic cardiovascular disease Pooled Cohort risk equations. , 2014, JAMA.

[25]  I. Ford,et al.  Long-term impact on healthcare resource utilization of statin treatment, and its cost effectiveness in the primary prevention of cardiovascular disease: a record linkage study , 2013, European heart journal.

[26]  A. Folsom,et al.  Twenty-Two–Year Trends in Incidence of Myocardial Infarction, Coronary Heart Disease Mortality, and Case Fatality in 4 US Communities, 1987–2008 , 2012, Circulation.

[27]  L. Goldman,et al.  Cost-Effectiveness of Statin Therapy for Primary Prevention in a Low-Cost Statin Era , 2011, Circulation.

[28]  R. Kronmal,et al.  Coronary calcium as a predictor of coronary events in four racial or ethnic groups. , 2008, The New England journal of medicine.

[29]  T. Gaziano.  Economic burden and the cost-effectiveness of treatment of cardiovascular diseases in Africa , 2008, Heart.

[30]  S. Yusuf,et al.  Risk factors for early myocardial infarction in South Asians compared with individuals in other countries. , 2007, JAMA.

[31]  R. D'Agostino,et al.  Prediction of Lifetime Risk for Cardiovascular Disease by Risk Factor Burden at 50 Years of Age , 2006, Circulation.

[32]  V. Fuster,et al.  Long-term air pollution exposure and acceleration of atherosclerosis and vascular inflammation in an animal model. , 2005, JAMA.

[33]  R. Califf,et al.  Ezetimibe Added to Statin Therapy after Acute Coronary Syndromes. , 2015, The New England journal of medicine.

[34]  Third Report of the National Cholesterol Education Program (NCEP) Expert Panel on Detection, Evaluation, and Treatment of High Blood Cholesterol in Adults (Adult Treatment Panel III) final report. , 2002, Circulation.

[35]  Rajeev Gupta,et al.  Vascular Health and Risk Management Dovepress Open Access to Scientific and Medical Research Open Access Full Text Article Low Use of Statins and Other Coronary Secondary Prevention Therapies in Primary and Secondary Care in India Background , 2022 .